Harnessing the (anything but ordinary) power of niacinamide and zinc – with a surprisingly small price tag – this potent serum is perfect for combatting blemishes, enlarged pores and uneven skin tone. A must-have for battling breakouts, The Ordinary’s Niacinamide 10% + Zinc 1% regulates sebum production to minimise pores and reduce blemish-causing bacteria, keeping your complexion clear, calm and collected. A superlative skin improver, niacinamide boosts the skin’s immunity and improves moisture retention, while a brilliant shot of zinc PCA works to repair damaged skin and promote the creation of collagen.HOW TO USEApply to entire face morning and evening before heavier creams.INGREDIENTSAqua (Water), Niacinamide, Pentylene Glycol, Zinc PCA, Tamarindus Indica Seed Gum, Xanthan Gum, Isoceteth-20, Ethoxydiglycol, Phenoxyethanol, Chlorphenesin.
Niacinamide 10% + Zing 1% (By The Ordinary, 30ml)
Rs. 4,990.00
In stock
or make 3 interest free instalments of Rs. .1,663.33 with Koko

Reviews (0)
Be the first to review “Niacinamide 10% + Zing 1% (By The Ordinary, 30ml)” Cancel reply
Related products
COSRX BHA Blackhead Power Liquid (100ml)
Rs. 8,900.00or make 3 interest free instalments of Rs. .2,966.67 with Koko

The Ordinary Niacinamide 10% + Zinc 1% (60ml)
Rs. 7,990.00or make 3 interest free instalments of Rs. .2,663.33 with Koko

DR. BARBARA STURM ALOE VERA GEL
Rs. 5,990.00or make 3 interest free instalments of Rs. .1,996.67 with Koko

Bio-Oil Hydrating Dry Skin Gel 100ml
Rs. 7,500.00or make 3 interest free instalments of Rs. .2,500.00 with Koko

MEDIK8 C-TETRA LUXE 30ML
Rs. 19,990.00or make 3 interest free instalments of Rs. .6,663.33 with Koko

The Ordinary Salicylic Acid 2% Solution
Rs. 4,990.00or make 3 interest free instalments of Rs. .1,663.33 with Koko

The Ordinary Ascorbyl Glucoside Solution 12% (30ml)
Rs. 8,990.00or make 3 interest free instalments of Rs. .2,996.67 with Koko

CeraVe SA Smoothing Cleanser (236ml)
Rs. 8,500.00or make 3 interest free instalments of Rs. .2,833.33 with Koko

Reviews
There are no reviews yet.